Homoeopathic Medicines in skin fungal infections

A Multicentric, Open label, Prospective, Observational Study to evaluate effect of Individualised Homoeopathic Medicines in Tinea Corporis and Tinea Cruris

Status

Active, not recruiting

Phases

Phase 3

Study type

Observational

Source

CTRI

Registry ID

CTRI/2021/07/034640

Enrollment

198

Registered

2021-07-06

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B354- Tinea corporis Health Condition 2: B356- Tinea cruris

Interventions

Intervention1: Individualized Homoeopathic medicine: Homoeopathic medicines in sugar pills of size 30 based on presenting signs and symptoms,for 15 days maximum of 3 doses in a day to be given. Contro

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 18-65 years with Tinea corporis/cruris. Both male and female Patientâ??s positive with Mycological findings

Exclusion criteria

Exclusion criteria: Patients using topical ointments /systemic treatment for tinea in past 15days. Evidence of skin conditions (like Tinea pedis/ barbae/ unguium, Pityriasis versicolor/ Alba, vitiligo, Psoriasis, Eczema, Lichen planus) other than Tinea corporis / Cruris that would interfere with evaluations of the effect of study medication. Patients taking treatment with immune-modulating oral medications in past one (1) month. Cases associated with any systemic diseases and their complications (like Diabetes mellitus, primary or secondary Hypertension, Thyroid disorders, Any heart diseases, Renal failure or Hepatic failure, any type of malignancy, HIV, Tuberculosis, Filariasis). Pregnant or Lactating women. Unwilling to participate the study.

Design outcomes

Primary

Measure	Time frame
Clinical and Mycological assessment of Tinea lesion at baseline, and end of Treatment Clinical cure (resolution of sign and symptoms) Mycological assessment is based on KOH mounting for dermatophytes Timepoint: Patient will be examined at baseline visit on day 0 and thereafter at 2 weeks interval upto 06 months	—

Secondary

Measure	Time frame
Global Evaluation Response by the physician Evaluation of effect on Quality of life of Tinea patients using SKINDEX 16 Timepoint: baseline,at interval of 15 days till end of treatment	—

Countries

India

Contacts

Public ContactDr Renu Mittal

Central Council for Research in Homoeopathy

renumittal8@gmail.com9717511115

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026